Literature DB >> 29795765

Discovery and Design of First Benzylamine-Based Ligands Binding to an Unlocked Conformation of the Complement Factor D.

Anna Vulpetti1, Nils Ostermann1, Stefan Randl1, Taeyoung Yoon1, Aengus Mac Sweeney1, Frederic Cumin1, Edwige Lorthiois1, Simon Rüdisser1, Paul Erbel1, Jürgen Maibaum1.   

Abstract

Complement Factor D, a serine protease of the S1 family and key component of the alternative pathway amplification loop, represents a promising target for the treatment of several prevalent and rare diseases linked to the innate immune system. Previously reported FD inhibitors have been shown to bind to the FD active site in its self-inhibited conformation characterized by the presence of a salt bridge at the bottom of the S1 pocket between Asp189 and Arg218. We report herein a new set of small-molecule FD ligands that harbor a basic S1 binding moiety directly binding to the carboxylate of Asp189, thereby displacing the Asp189-Arg218 ionic interaction and significantly changing the conformation of the self-inhibitory loop.

Entities:  

Year:  2018        PMID: 29795765      PMCID: PMC5949727          DOI: 10.1021/acsmedchemlett.8b00104

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  19 in total

1.  The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex.

Authors:  Jeffrey T Kohrt; Kevin J Filipski; Wayne L Cody; Cuiman Cai; Danette A Dudley; Chad A Van Huis; J Adam Willardsen; Stephen T Rapundalo; Kamlai Saiya-Cork; Robert J Leadley; Lakshmi Narasimhan; Erli Zhang; Marc Whitlow; Marc Adler; Kirk McLean; Yuo-Ling Chou; Cecile McKnight; Damian O Arnaiz; Kenneth J Shaw; David R Light; Jeremy J Edmunds
Journal:  Bioorg Med Chem Lett       Date:  2005-11-01       Impact factor: 2.823

Review 2.  Complement factor D, a novel serine protease.

Authors:  J E Volanakis; S V Narayana
Journal:  Protein Sci       Date:  1996-04       Impact factor: 6.725

3.  Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors.

Authors:  Anna Vulpetti; Stefan Randl; Simon Rüdisser; Nils Ostermann; Paul Erbel; Aengus Mac Sweeney; Thomas Zoller; Bahaa Salem; Bernd Gerhartz; Frederic Cumin; Ulrich Hommel; Claudio Dalvit; Edwige Lorthiois; Jürgen Maibaum
Journal:  J Med Chem       Date:  2017-02-20       Impact factor: 7.446

4.  (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.

Authors:  S Sperl; U Jacob; N Arroyo de Prada; J Stürzebecher; O G Wilhelm; W Bode; V Magdolen; R Huber; L Moroder
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

5.  Structure of human factor D. A complement system protein at 2.0 A resolution.

Authors:  S V Narayana; M Carson; O el-Kabbani; J M Kilpatrick; D Moore; X Chen; C E Bugg; J E Volanakis; L J DeLucas
Journal:  J Mol Biol       Date:  1994-01-14       Impact factor: 5.469

6.  Small-molecule factor D inhibitors targeting the alternative complement pathway.

Authors:  Jürgen Maibaum; Sha-Mei Liao; Anna Vulpetti; Nils Ostermann; Stefan Randl; Simon Rüdisser; Edwige Lorthiois; Paul Erbel; Bernd Kinzel; Fabrice A Kolb; Samuel Barbieri; Julia Wagner; Corinne Durand; Kamal Fettis; Solene Dussauge; Nicola Hughes; Omar Delgado; Ulrich Hommel; Ty Gould; Aengus Mac Sweeney; Bernd Gerhartz; Frederic Cumin; Stefanie Flohr; Anna Schubart; Bruce Jaffee; Richard Harrison; Antonio Maria Risitano; Jörg Eder; Karen Anderson
Journal:  Nat Chem Biol       Date:  2016-10-24       Impact factor: 15.040

7.  Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.

Authors:  Michael D Wendt; Andrew Geyer; William J McClellan; Todd W Rockway; Moshe Weitzberg; Xumiao Zhao; Robert Mantei; Kent Stewart; Vicki Nienaber; Vered Klinghofer; Vincent L Giranda
Journal:  Bioorg Med Chem Lett       Date:  2004-06-21       Impact factor: 2.823

8.  Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).

Authors:  Christopher W West; Marc Adler; Danny Arnaiz; Deborah Chen; Kieu Chu; Giovanna Gualtieri; Elena Ho; Christoph Huwe; David Light; Gary Phillips; Rebecca Pulk; Drew Sukovich; Marc Whitlow; Shendong Yuan; Judi Bryant
Journal:  Bioorg Med Chem Lett       Date:  2009-08-07       Impact factor: 2.823

9.  Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.

Authors:  Michael N Greco; Michael J Hawkins; Eugene T Powell; Harold R Almond; Lawrence de Garavilla; Jeffrey Hall; Lisa K Minor; Yuanping Wang; Thomas W Corcoran; Enrico Di Cera; Angelene M Cantwell; Savvas N Savvides; Bruce P Damiano; Bruce E Maryanoff
Journal:  J Med Chem       Date:  2007-03-16       Impact factor: 7.446

10.  Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Authors:  Xuan Yuan; Eleni Gavriilaki; Jane A Thanassi; Guangwei Yang; Andrea C Baines; Steven D Podos; Yongqing Huang; Mingjun Huang; Robert A Brodsky
Journal:  Haematologica       Date:  2016-11-03       Impact factor: 9.941

View more
  1 in total

Review 1.  Novel Insights into Factor D Inhibition.

Authors:  Eleni Gavriilaki; Anna Papakonstantinou; Konstantinos A Agrios
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.